Currie Marian J, Reynolds Graham J, Glasgow Nicholas J, Bowden Francis J
Australian National University Medical School, Canberra Hospital, WODEN ACT, Australia.
Pediatr Dermatol. 2010 Nov-Dec;27(6):595-9. doi: 10.1111/j.1525-1470.2010.01317.x.
Head lice are a common, costly public health problem worldwide. We aimed to determine the feasibility of an ivermectin intervention program. Consenting students in two schools were screened for head lice. Infested students and siblings at one school were offered a head lice fact sheet and two doses of oral ivermectin, 7 days apart. Parents of infested students in the other school were given the same fact sheet and asked to treat the child and siblings using their preferred topical treatment. Seven hundred two of 754 (93.1%) students enrolled in the two schools were screened; 40 (5.3%; 95% CI 3.7-6.9) had head lice; 31 (9.4%; 95% CI 6.1-12.2) in the intervention school and nine (2.5%; 95% CI 1.1-3.8) in the control school. Subsequently 93.6% of children in the intervention school were treated with oral ivermectin. No adverse events were reported. At 6 months the reduction in the head lice infestation rates for the intervention and control schools were 87% and 56%, respectively. This pilot study suggests that school wide screening for head lice and the administration of oral ivermectin is feasible and acceptable. A randomized controlled trial at 20 schools is planned.
头虱是全球范围内一个常见且代价高昂的公共卫生问题。我们旨在确定伊维菌素干预项目的可行性。对两所学校中同意参与的学生进行头虱筛查。一所学校中受感染的学生及其兄弟姐妹会收到一份头虱情况说明书,并分7天间隔服用两剂口服伊维菌素。另一所学校中受感染学生的家长收到相同的情况说明书,并被要求使用他们偏好的局部治疗方法来治疗孩子及其兄弟姐妹。两所学校共754名注册学生中的702名(93.1%)接受了筛查;40名(5.3%;95%置信区间3.7 - 6.9)有头虱;干预学校中有31名(9.4%;95%置信区间6.1 - 12.2),对照学校中有9名(2.5%;95%置信区间1.1 - 3.8)。随后,干预学校中93.6%的儿童接受了口服伊维菌素治疗。未报告不良事件。在6个月时,干预学校和对照学校的头虱感染率分别降低了87%和56%。这项试点研究表明,全校范围的头虱筛查和口服伊维菌素给药是可行且可接受的。计划在20所学校开展一项随机对照试验。